Last reviewed · How we verify
RCT1100
At a glance
| Generic name | RCT1100 |
|---|---|
| Sponsor | ReCode Therapeutics |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance (PHASE1)
- A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults With PCD (PHASE1)
- Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RCT1100 CI brief — competitive landscape report
- RCT1100 updates RSS · CI watch RSS
- ReCode Therapeutics portfolio CI